ePrints

Novel strategies and therapeutic options for the management of primary biliary cholangitis

Lookup NU author(s): Dr Amardeep Khanna, Professor David Jones

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© SAGE Publications. Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease. It has a varied course of progression ranging from being completely asymptomatic to aggressive disease leading to cirrhosis and resulting in liver transplantation. In addition, symptoms can be debilitating and can have a major impact on quality of life. For decades, there was only one anti-cholestatic agent available to target this disease and that was only effective in around half of patients, with little or no effect on symptoms. With increasing understanding of the pathogenic mechanisms of PBC and potential targets for drug treatment, pharmaceutical companies have shown a greater interest in this rare disease. A large number of novel therapeutic molecules have been developed and are currently being evaluated. In this review article all the novel molecules in use and in trials targeting cholestasis and symptoms in PBC are discussed.

Publication metadata

Author(s): Khanna A, Jones DE

Publication type: Review

Publication status: Published

Journal: Therapeutic Advances in Gastroenterology

Year: 2017

Volume: 10

Issue: 10

Pages: 791-803

Print publication date: 01/10/2017

Online publication date: 07/09/2017

Acceptance date: 25/07/2017

ISSN (print): 1756-283X

ISSN (electronic): 1756-2848

Publisher: SAGE Publications Ltd

URL: https://doi.org/10.1177/1756283X17728669

DOI: 10.1177/1756283X17728669

Share